Eli Lilly (NYSE:LLY) announced the acquisition of Orna Therapeutics to expand into circular RNA based gene and autoimmune ...

Feb 9 (Reuters) - Eli Lilly will buy therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said ...

Diabetic foot ulcers are slow-healing and increase the risk of infections and amputation. Researchers at Karolinska ...

Circular Genomics, a molecular diagnostics company pioneering circular RNA (circRNA)–based biomarkers for neurodegenerative disease, today announced the completion of exclusive intellectual property ...

Eli Lilly (LLY) has agreed to acquire biotechnology company Orna Therapeutics for up to $2.4B in cash, inclusive of an ...

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

Deep within our nerve cells, a molecule is at work that has no beginning and no end. Instead of a straight chain, as is common for most RNA strands, it forms a closed loop. Known as circular RNAs ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.

Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics for up to $2.4b, adding circular RNA and in vivo CAR T technology to its drug development toolkit. The company also expanded ...

Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negotiate licensing agreement Altamira Therapeutics Ltd.